Yulin J. Lai

NO. 38 Jinglong Jianshe Road
Shenzhen, 518109, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Urethral diverticulum carcinoma management: a case report and review of the literature.

Urethral diverticulum carcinoma management: a case report and review of the literature.

Journal: Journal of medical case reports

Published: February 19, 2025

Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.

Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.

Journal: Cancer medicine

Published: November 22, 2024

Machine learning identifies the association between second primary malignancies and postoperative radiotherapy in young-onset breast cancer patients.

Machine learning identifies the association between second primary malignancies and postoperative radiotherapy in young-onset breast cancer patients.

Journal: PloS one

Published: July 20, 2024

Retraction notice to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" Biomed. Pharmacother. 110(2019) 656-666.

Retraction notice to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" Biomed. Pharmacother. 110(2019) 656-666.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 06, 2024

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial.

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial.

Journal: BMC medicine

Published: May 07, 2024

Erratum: [Corrigendum] miR‑199b‑5p serves as a tumor suppressor in renal cell carcinoma.

Erratum: [Corrigendum] miR‑199b‑5p serves as a tumor suppressor in renal cell carcinoma.

Journal: Experimental and therapeutic medicine

Published: February 28, 2024

Analysis of success rate of organoid construction of nasopharyngeal carcinoma by first-day suspension method

Analysis of success rate of organoid construction of nasopharyngeal carcinoma by first-day suspension method

Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Published: March 06, 2023

Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism.

Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism.

Journal: Frontiers in oncology

Published: September 06, 2022

OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism.

OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism.

Journal: Frontiers in oncology

Published: June 24, 2022

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial.

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial.

Journal: EClinicalMedicine

Published: June 02, 2022

The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.

The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.

Journal: Cancer medicine

Published: May 03, 2022

A Panel of Three Serum MicroRNAs as a Potential Diagnostic Biomarker for Urothelial Carcinoma.

A Panel of Three Serum MicroRNAs as a Potential Diagnostic Biomarker for Urothelial Carcinoma.

Journal: Oncology research and treatment

Published: November 02, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026